Keryx Biopharmaceuticals Sees Unusually High Options Volume (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) was the target of unusually large options trading on Monday. Traders bought 4,730 call options on the stock, Stock Ratings News reports. This represents an increase of approximately 289% compared to the average daily volume of 1,215 call options.
A number of research firms have recently commented on KERX. Analysts at FBR Capital Markets initiated coverage on shares of Keryx Biopharmaceuticals in a research note on Wednesday, August 13th. They set a “market perform” rating and a $16.00 price target on the stock. Analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $32.00 to $30.00 in a research note on Friday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.10.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 8.43% on Monday, hitting $17.23. The stock had a trading volume of 3,649,849 shares. Keryx Biopharmaceuticals has a 52 week low of $8.48 and a 52 week high of $17.46. The stock has a 50-day moving average of $15.35 and a 200-day moving average of $14.90. The company’s market cap is $1.582 billion.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Analysts expect that Keryx Biopharmaceuticals will post $-0.89 EPS for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.